Skip to main content

Search

Reset all filters
605 Result(s)
Sort by

Interview with Michael Schmelmer

Interview with Michael Schmelmer

"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Anna Race

Anna Race

Anna Race, Sales Director, Human Pharma, UK & Ireland, tells us how a career in our Commercial Division helps her to make a difference.
Who are we?

Who are we?

Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Health Equity: No distance is too far

Health Equity: No distance is too far

India is hosting the G20 summit. The leading theme of the G20 summit emphasizes health equity and sustainability as part of the agenda. How we provide access to healthcare for rural areas in India.
Co-creation with Communities

Co-creation with Communities

Making More Health has launched co-creation projects in Asia, Africa, Europe and other localities around the world with top social entrepreneurs.
Focus on Alliance Management

Focus on Alliance Management

Stefan Walke, Global Head of Alliance Management, shares his perspectives on Alliance Management and its contribution to the development of successful long-term partnerships.
Access to Healthcare Strategy Sustainable Access Models

Access to Healthcare Strategy Sustainable Access Models

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
LastMile – improving through digital

LastMile – improving through digital

LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
Speak Up – Compliance Hotline

Speak Up – Compliance Hotline

The Speak Up portal provides a safe environment to report potential violations and is open to any person worldwide. We take any reports of potential violations seriously.
ATM-Ranking-2021

ATM-Ranking-2021

Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
What we do

What we do

Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Mental Health

Mental Health

Human Pharma Clinical Pipeline Mental Health therapeutic area
collaboration-kings-college-london

collaboration-kings-college-london

Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Dirk Stenkamp

Dirk Stenkamp

Dirk Stenkamp, Senior Vice President Research Site Germany, reflects on our culture of collaboration and passion for progress.
Sant Cugat del Vallès

Sant Cugat del Vallès

The site in Sant Cugat del Vallès focuses on pharmaceutical production and is one of the production sites of the RESPIMAT®.
NeO - smart and sustainable vaccines

NeO - smart and sustainable vaccines

The reduction in the environmental impact of the new NeO vaccine packaging illustrates Boehringer Ingelheim’s drive for environmental responsibility.
Rewards and recognition

Rewards and recognition

There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.